Granules India Limited
All news and filings related to Granules India Limited.
View all news & filings- Medium impact
Granules India Granted Potential Sole First-to-File Status for Ruxolitinib ANDA
Granules India Limited submitted a Paragraph IV certification for its Ruxolitinib Extended-Release Tablets ANDA. The company believes it is eligible for first-to-file status, potentially leading to 180 days of generic drug exclusivity, pending FDA review and confirmation.
Read the summary - High impact
Granules India Releases Webinar Transcript, Outlines Multi-Engine Growth Strategy
Granules India released its webinar transcript detailing a multi-engine growth strategy focused on controlled substances, complex generics, oncology, and peptide CDMO. The company aims for substantial earnings growth and a differentiated portfolio, leveraging ₹2,000 crore capex over 3-4 years. Peptide CDMO targets $50M revenue in 3 years and $100M in 5 years. Investments will be milestone-based.
Read the summary - Low impact
Granules India Incorporates Wholly Owned Subsidiary in Brazil
Granules India Limited has incorporated a wholly owned foreign subsidiary, TRITON FARMACEUTICA DO BRASIL LTDA, in Brazil. The subsidiary aims to manufacture, promote, sell, and distribute pharmaceuticals. This move required prior RBI approval.
Read the summary - Low impact
Granules India Ltd Uploads Audio Recording of Webinar Held on Sep 29, 2026
Granules India Limited has uploaded the audio recording of a webinar held on September 29, 2026. The recording is available on the company's website as per SEBI regulations. This follows an earlier intimation about the webinar schedule.
Read the summary - Medium impact
Granules India to host IIFL Capital Webinar on Transformation Journey on Sep 29
Granules India will participate in an IIFL Capital webinar on Sep 29, 2026, discussing its transformation journey. The focus will be on controlled substances, complex formulations, oncology, FTF opportunities, and peptide CDMO, targeting USD 100 million revenue in 4-5 years.
Read the summary - Low impact
Granules India: Trading Window Closed for Q2 FY27 Results
Granules India Limited will close its trading window from October 01, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the second quarter and half-year ended September 30, 2026. This is in compliance with SEBI regulations.
Read the summary - Low impact
Granules India to Meet Analysts/Investors on Sep 28 in New Delhi
Granules India Limited management will meet analysts and investors on September 28, 2026, in New Delhi. No unpublished price-sensitive information will be disclosed. The latest investor presentation is available on the company's website.
Read the summary - Medium impact
Granules India Allots 2.5 Cr Equity Shares Worth ₹1461.5 Cr to Promoter Group
Granules India allotted 2,49,82,906 equity shares to its promoter group. The conversion of warrants was completed upon receipt of the balance subscription amount. The total consideration for the allotment is ₹1,461.50 Crores at an issue price of ₹585 per share. This increases the company's paid-up equity share capital.
Read the summary - Medium impact
Granules India Limited Receives ₹1,093 Crore, Strengthens Net Cash Position
Granules India Limited received ₹1,093 crore, the balance subscription amount for convertible warrants issued on a private placement basis. Following this, 2,49,14,530 warrants are eligible for conversion into equity shares. The company will now be in a net cash surplus position, enhancing its flexibility for growth deployment.
Read the summary - Medium impact
Granules India Promoter Sells 1.72 Cr Shares, Stake Drops to 31.08%
Dr. Krishna Prasad Chigurupati, Promoter of Granules India, sold 1.72 crore shares on September 11, 2026. The sale funded the second tranche of the company's preferential issue and growth initiatives. Promoter Group's stake reduced from 38.02% to 31.08%.
Read the summary - Low impact
Granules India to Meet Analysts/Investors on Sep 18, 2026
Granules India Limited's management will meet analysts and investors on September 18, 2026, in Hyderabad. No unpublished price-sensitive information will be disclosed during the meeting. The investor presentation is available on the company's website.
Read the summary - Low impact
Granules India Transfers Chief Strategy Officer to Subsidiary
Granules India Limited has transferred Mr. Sanjay Kumar, Chief Strategy Officer, to its subsidiary Ascelis Peptides Private Limited as CEO. The change is effective August 13, 2026. This move aims to provide dedicated leadership to the subsidiary.
Read the summary - Medium impact
Granules India Limited holds 35th AGM, approves FY26 financial statements and final dividend
Granules India Limited held its 35th AGM on August 06, 2026. Shareholders approved the FY26 financial statements and a final dividend of ₹1.75 per equity share. Ms. Priyanka Chigurupati was re-appointed as a Director. All resolutions passed with requisite majority.
Read the summary - High impact
Granules India Q1 FY27 Earnings Call Transcript Released
Granules India reported a strong Q1 FY27 with 22% YoY revenue growth to INR 1,477 crore and 60% PAT growth to INR 180 crore. EBITDA rose 37% to INR 339 crore. The company is focusing on complex generics (50% of finished dosages) and its peptide CDMO business. Remediation at Gagillapur is nearing completion. Capex for FY27 is guided at INR 600 crore.
Read the summary - Low impact
Granules India Releases Q1 FY27 Earnings Conference Call Audio Recording
Granules India Limited has uploaded the audio recording of its Q1 FY27 earnings conference call to its website. The recording is now available for investors. This follows the prior intimation of the call schedule on July 09, 2026.
Read the summary - Low impact
Granules India: Monitoring Agency Report for Q1 FY27 Confirms No Deviation in Preferential Issue Proceeds
Granules India's Monitoring Agency Report for Q1 FY27 confirms no deviation in preferential issue proceeds. The company raised ₹1,762.50 Crores and utilized ₹218.14 Crores in the quarter. Key utilizations included loan prepayments and general corporate purposes. Unutilized funds of ₹414.65 Crores remain.
Read the summary - Medium impact
Granules India Q1 FY27 Results: Standalone Profit Declines to ₹717.46 Cr, Consolidated Profit at ₹1,799.63 Cr
Granules India reported Q1 FY27 results with standalone profit at ₹717.46 crore, down from ₹989.87 crore year-on-year. Consolidated profit surged to ₹1,799.63 crore from ₹701.56 crore. Standalone revenue was ₹8,018.77 crore, and consolidated revenue was ₹14,767.74 crore.
Read the summary - Low impact
Granules India Publishes AGM Notice in Newspapers
Granules India Limited published its 35th Annual General Meeting notice and e-voting details in Business Standard and Nava Telangana on July 16, 2026. The company provided the newspaper publication as an enclosure.
Read the summary - Medium impact
Granules India Submits FY26 Annual Report & Announces 35th AGM on Aug 6
Granules India submitted its FY26 Integrated Annual Report and announced its 35th AGM for August 6, 2026. The report highlights revenue of ₹53,656 million (up 20%) and EBITDA of ₹11,851 million (up 25%). The company also detailed progress in complex generics, peptide CDMO through Senn Chemicals acquisition, and sustainability efforts.
Read the summary - Low impact
Granules India Schedules Q1 FY27 Earnings Conference Call for July 21, 2026
Granules India Limited will host its Q1 FY27 Earnings Conference Call on Tuesday, July 21, 2026, at 5:00 PM IST. The call will feature discussions on financial performance and business updates with key management personnel. Dial-in details and a pre-registration link are provided.
Read the summary - Medium impact
Granules India Secures Sole First-to-File ANDA for Sodium Oxybate ER
Granules India Limited announced on July 6, 2026, it secured Sole First-to-File (FTF) ANDA status for Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of LUMRYZ®. This is Granules' second FTF ANDA, reinforcing its R&D and regulatory capabilities in complex generics.
Read the summary - Low impact
Granules India: Trading Window Closed July 1 to Post-Q1 FY27 Results
Granules India Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of Q1 FY27 un-audited financial results, ending June 30, 2026.
Read the summary - Low impact
Granules India to Meet Analysts/Investors in London on June 23-24
Granules India Limited will participate in the IIFL Invest India Conference in London on June 23-24, 2026. Company officials will hold one-to-one and group meetings with analysts and investors. No unpublished price-sensitive information will be disclosed.
Read the summary - Medium impact
Granules Pharma Receives USFDA EIR for Chantilly Facility with VAI Classification
Granules Pharmaceuticals, Inc., a subsidiary of Granules India Limited, has received an Establishment Inspection Report (EIR) from the USFDA for its Chantilly, Virginia facility. The facility received a Voluntary Action Indicated (VAI) classification. The inspection took place from March 30 to April 3, 2026, with four Form 483 observations issued.
Read the summary - Low impact
Granules India to Meet Analysts/Investors on June 3, 2026
Granules India Limited will host an investor meeting on June 03, 2026, in Hyderabad. The company will meet with analysts, investors, and funds. No unpublished price-sensitive information will be shared during the meeting.
Read the summary - Low impact
Granules India Clarifies Volume Surge; Cites Market Driven Factors
Granules India Limited clarified that the recent significant increase in its stock trading volume is purely market driven. The company affirmed its adherence to SEBI regulations for timely disclosure of price-sensitive information that could impact trading volume.
Read the summary - Medium impact
Granules India Q4 FY26 Earnings Call Transcript Released
Granules India reported FY26 revenue of INR 53,656 million, a 20% YoY increase. EBITDA grew 25% to INR 11,851 million, with margins at 22.1%. The peptide CDMO business generated INR 1,593 million revenue. Net debt reduced to INR 4,021 million. The company is focused on FDA readiness, complex products, and scaling CDMO operations.
Read the summary - Low impact
Granules India Releases Q4 FY26 Earnings Conference Call Audio Recording
Granules India Limited has released the audio recording of its Q4 and FY26 earnings conference call. The recording covers results for the year ended March 31, 2026, and is available on the company website as per SEBI regulations.
Read the summary - Medium impact
Granules India Board Approves Audited FY26 Financial Results
Granules India Limited's Board approved audited standalone and consolidated results for FY26. For FY26, standalone revenue was ₹35,237.63 million and profit after tax was ₹4,006.67 million. Consolidated revenue was ₹53,859.71 million and profit after tax was ₹5,950.21 million. A final dividend of ₹1.75 per share was recommended.
Read the summary - Low impact
Granules India sets July 30, 2026 as Record Date for Final Dividend
Granules India Limited has fixed July 30, 2026, as the record date for its final dividend for the financial year ended March 31, 2026. This decision complies with SEBI's Listing Obligations and Disclosure Requirements.
Read the summary - Low impact
Granules India: No Deviation in Utilization of Preferential Issue Proceeds for Q4FY26
Granules India Limited's Monitoring Agency Report for the quarter ended March 31, 2026, confirms no deviation in the utilization of funds from its Preferential Issue. The company raised ₹1,762.50 Crores, receiving ₹665.63 Crores by March 31, 2026. The report, issued by India Ratings, covers the use of proceeds for investments, operating expenses, and general corporate purposes.
Read the summary - High impact
Granules India Q4FY26 Revenue Up 23% YoY to ₹14,706 Mn; PAT Rises 33%
Granules India reported Q4FY26 revenue of ₹14,706 Mn, up 23% YoY. EBITDA increased 40% to ₹3,521 Mn, and PAT grew 33% to ₹2,016 Mn. For FY26, revenue was ₹53,656 Mn (+20% YoY) and PAT was ₹5,950 Mn (+19% YoY). Net debt reduced by ₹3,040 Mn YoY.
Read the summary - High impact
Granules India FY26 Revenue Surges 20% to ₹53,656 Mn; PAT Grows 19% to ₹5,950 Mn
Granules India reported FY26 revenue of ₹53,656 Mn, up 20% YoY, and PAT of ₹5,950 Mn, up 19% YoY. Q4FY26 revenue increased 23% YoY to ₹14,706 Mn, with PAT up 33% YoY to ₹2,016 Mn. The company achieved record gross margins of 65.0% for FY26 and 22.1% EBITDA margin. Strategic focus on Complex Gx and CDMO business contributed to growth.
Read the summary - Low impact
Granules India Appoints Harsha Chigurupati as Senior Management Personnel
Granules India Limited has designated Mr. Harsha Chigurupati, Executive Director, as Senior Management Personnel. This appointment is effective April 30, 2026, and he will oversee Transformation & IT, Project Management, and Leadership Hiring.
Read the summary - Medium impact
Granules India Board Approves FY26 Results, Recommends ₹1.75 Dividend, Sets AGM for Aug 6
Granules India announced its audited Q4 and FY26 results. The company recommended a final dividend of ₹1.75 per share. The 35th AGM is scheduled for August 6, 2026, with a dividend record date of July 30, 2026. Standalone profit before tax was ₹5,358.14 million, and consolidated profit before tax was ₹7,849.81 million.
Read the summary - Medium impact
Granules India Reports Audited FY26 Results; Recommends Dividend
Granules India announced audited standalone and consolidated results for FY26. The Board recommended a final dividend of ₹1.75 per share. The company completed acquisitions of Senn Chemicals AG and Granules Pharmaceuticals GmbH. It also raised funds via preferential allotment of warrants.
Read the summary - Low impact
Granules India schedules Q4 FY26 earnings conference call for April 29, 2026
Granules India Limited will hold its Q4 and full fiscal year 2026 earnings conference call on April 29, 2026, at 5:00 PM IST. The call will cover financial performance and business updates. Key management, including the Chairman & MD, will be present. International and domestic dial-in details are provided.
Read the summary - Low impact
Granules India's US Subsidiary Completes FDA cGMP Audit with 4 Observations
Granules India's US subsidiary, Granules Pharmaceuticals, Inc., completed a routine US FDA cGMP audit with four Form 483 observations. The inspection took place from March 30 to April 3, 2026. The observations are procedural, with no data integrity issues reported. The company will address these within timelines.
Read the summary - Low impact
Granules India: Promoter Group Declares No New Encumbrances
Granules India Limited's promoter group, led by Dr. Krishna Prasad Chigurupati, declared no new encumbrances on company shares as of April 1, 2026. This declaration is in compliance with SEBI Takeover Regulations for the financial year ending March 31, 2026.
Read the summary - Medium impact
Granules Life Sciences gets US FDA VAI Classification for Telangana facility
Granules India's subsidiary, Granules Life Sciences, received a Voluntary Action Indicated (VAI) classification from the US FDA for its Telangana facility. The inspection, conducted from December 15-19, 2025, concluded with no regulatory actions recommended. This strengthens the company's finished dosage manufacturing capabilities.
Read the summary - Low impact
Granules India Closes Trading Window from April 1, 2026 for FY26 Audited Results
Granules India Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of audited financial results for the quarter and financial year ending March 31, 2026. This is a routine compliance measure.
Read the summary - Medium impact
Granules India's US Packaging Facility Receives FDA EIR with NAI Status
Granules India's US subsidiary, Granules Consumer Health, LLC, received a No Action Indicated (NAI) status from the FDA for its packaging facility in Manassas, Virginia. The inspection, conducted from December 1-3, 2025, resulted in zero observations, marking the second consecutive successful FDA audit.
Read the summary - Low impact
Granules India to Meet UBS Emerging India Mid-Caps on March 9-10, 2026
Granules India Limited announced an investor meeting with UBS Emerging India Mid-Caps on March 9-10, 2026, in Singapore. The meetings will be one-to-one and group sessions. No price-sensitive information will be disclosed.
Read the summary - Medium impact
Granules India Allots 2.5 Cr Warrants & 51 Lakh Shares on Preferential Basis
Granules India Limited approved the allotment of 2.50 crore convertible warrants and 51.28 lakh equity shares on a preferential basis. The issuance price for both was ₹585 per security. This move increases the company's paid-up equity share capital.
Read the summary - Medium impact
Granules India Approves Preferential Issue of Warrants and Equity Shares
Granules India's shareholders approved a preferential issue including up to 2.5 crore warrants and 51.28 lakh equity shares. The company will recompute security prices as per SEBI regulations. Proceeds will be invested in debt mutual funds, bank deposits, or government securities pending utilization for specified objects.
Read the summary - Medium impact
Granules India Q3 FY26 Earnings Call Transcript Released
Granules India released its Q3 FY26 earnings call transcript. The company reported Q3 FY26 revenue of ₹1,388 crore (up 22% YoY) and EBITDA of ₹308 crore (up 34% YoY). Progress was noted on the Gagillapur facility's FDA remediation. The company highlighted R&D filings and ESG improvements. A preferential issue was successfully completed to strengthen the balance sheet.
Read the summary - Low impact
Granules India Q3 FY26 Earnings Conference Call Audio Recording Uploaded
Granules India Limited has uploaded the audio recording of its Q3 FY26 earnings conference call. The recording is available on the company's website as per SEBI regulations.
Read the summary - High impact
Granules India Q3FY26 Revenue Jumps 22% YoY to ₹13,879 Mn; EBITDA Up 34%
Granules India reported Q3FY26 revenue of ₹13,879 million, up 22% YoY. EBITDA rose 34% to ₹3,081 million with a margin of 22.2%. PAT increased 28% to ₹1,502 million. Key updates include Brazil GMP certification and a CDP climate change rating upgrade to 'A'.
Read the summary - High impact
Granules India Q3FY26 Revenue Jumps 22% YoY to ₹13,879 Million, PAT up 28%
Granules India reported Q3FY26 revenue of ₹13,879 million, up 22% YoY. EBITDA rose 34% to ₹3,081 million and PAT increased 28% to ₹1,502 million. The growth was driven by the Finished Dosages segment. ROCE stood at 16.8% and Net debt to EBITDA was 0.91x.
Read the summary - High impact
Granules India Q3FY26 Results: Revenue ₹8,953 Cr, Profit ₹1,116 Cr
Granules India reported Q3FY26 revenue of ₹8,953 crore and profit of ₹1,116 crore. Consolidated revenue stood at ₹13,879 crore with profit at ₹1,502 crore. The company acquired Granules Pharmaceuticals GmbH and approved capital raising of ₹14,625 crore via warrants and ₹3,000 crore via equity.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio